SHPH vs. KTTA, CVKD, HEPA, TENX, VCNX, IBIO, VIRI, BFRI, PULM, and ASLN
Should you be buying Shuttle Pharmaceuticals stock or one of its competitors? The main competitors of Shuttle Pharmaceuticals include Pasithea Therapeutics (KTTA), Cadrenal Therapeutics (CVKD), Hepion Pharmaceuticals (HEPA), Tenax Therapeutics (TENX), Vaccinex (VCNX), iBio (IBIO), Virios Therapeutics (VIRI), Biofrontera (BFRI), Pulmatrix (PULM), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical preparations" industry.
Pasithea Therapeutics (NASDAQ:KTTA) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking.
Pasithea Therapeutics received 2 more outperform votes than Shuttle Pharmaceuticals when rated by MarketBeat users.
Shuttle Pharmaceuticals has lower revenue, but higher earnings than Pasithea Therapeutics.
Pasithea Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.18, suggesting that its stock price is 218% less volatile than the S&P 500.
In the previous week, Shuttle Pharmaceuticals had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Shuttle Pharmaceuticals and 0 mentions for Pasithea Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 0.82 beat Pasithea Therapeutics' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.
23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 14.1% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 40.6% of Shuttle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Shuttle Pharmaceuticals' return on equity of -60.06% beat Pasithea Therapeutics' return on equity.
Summary
Pasithea Therapeutics beats Shuttle Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
Get Shuttle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SHPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shuttle Pharmaceuticals Competitors List
Related Companies and Tools
